RNAC
NASDAQCartesian Therapeutics Inc.
$6.74-0.14 (-2.03%)
News25/Ratings9
Price$6.74-0.17 (-2.46%)
01:30 PM07:45 PM
News · 26 weeks49-20%
2025-10-262026-04-19
Mix1290d
- Other5(42%)
- SEC Filings3(25%)
- Insider3(25%)
- Analyst1(8%)
Latest news
25 items- INSIDERSEC Form 4 filed by Hoge Elizabeth4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERSEC Form 4 filed by Kalayoglu Murat4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- PRCartesian Therapeutics Announces New Employment Inducement GrantsFREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company's common stock with an exercise price of $6.39, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Co
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- INSIDERDirector Singer Michael gifted 6,555 units of Common Stock, decreasing direct ownership by 12% to 49,578 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- ANALYSTCartesian Therapeutics upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded Cartesian Therapeutics from Neutral to Overweight and set a new price target of $16.00
- SECSEC Form 10-K filed by Cartesian Therapeutics Inc.10-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business UpdateEnrollment continues to progress in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis Phase 2 TRITON trial of Descartes-08 in dermatomyositis and antisynthetase syndrome, expected to initiate in 1H26 Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis actively enrolling Approximately $126.9 million cash, cash equivalents and restricted cash as of December 31, 2025, expected to support planned operations into mid-2027, including completion of ongoing Phase 3 AURORA trial FREDERICK, Md., March 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("we", the "Company" or "Cartesian"), a late clinical-stage biotechnology company pioneering
- PRCartesian Therapeutics to Participate in Upcoming Investor ConferencesFREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April: A presentation at the 46th Annual TD Cowen Health Care Conference at 11:50 a.m. ET Monday, March 2, 2026A fireside chat at Leerink's Global Healthcare Conference at 10:00 a.m. ET on Monday, March 9, 2026A fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Monday, April 13, 2026 Live webcasts of the fireside chats and presentation are expect
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cartesian Therapeutics Inc.SCHEDULE 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
- PRCartesian Therapeutics Announces New Employment Inducement GrantsFREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company's common stock with an exercise price of $6.79, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Compa
- SECCartesian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
- PRCartesian Therapeutics Highlights Recent Progress and Outlines 2026 OutlookEnrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune dise
- INSIDERPresident and CEO Brunn Carsten sold $162,077 worth of shares (23,766 units at $6.82), decreasing direct ownership by 7% to 323,530 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERChief Financial Officer Davis Blaine sold $72,227 worth of Common Stock (10,591 units at $6.82), decreasing direct ownership by 8% to 121,220 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERChief Medical Officer Miljkovic Milos sold $24,367 worth of Common Stock (3,573 units at $6.82), decreasing direct ownership by 6% to 58,820 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERDirector Desilva Nishan M was granted 2,600 shares, increasing direct ownership by 30% to 11,366 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERPresident and CEO Brunn Carsten was granted 143,200 shares, increasing direct ownership by 70% to 347,296 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERDirector Malik Kemal was granted 2,600 units of Common Stock, increasing direct ownership by 30% to 11,133 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERChief Medical Officer Miljkovic Milos was granted 27,000 units of Common Stock, increasing direct ownership by 76% to 62,393 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERChief Accounting Officer Seymour June Ann was granted 6,500 units of Common Stock (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERDirector Zenner Patrick J was granted 2,600 shares, increasing direct ownership by 25% to 12,974 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERChief Financial Officer Davis Blaine was granted 37,000 units of Common Stock, increasing direct ownership by 39% to 131,811 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
- INSIDERDirector Barabe Timothy C was granted 2,600 shares, increasing direct ownership by 5% to 56,966 units (SEC Form 4)4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)